Somatic ERBB3-mutations have low incidence (typically <1%) across solid cancer types such as NSCLC and the oncogenic effect of ERBB3 depends on dimerization with other ERBB-family members because of its very weak intrinsic TK activity. This evidence concerns the gene ERBB3 and non-small cell lung carcinoma.